




**05**

# **Annexure**






Figure 2: Factors affecting policy design.



Source: Schneider and Larson. 1997. [1]

**Table 1:** Country scores on robustness of decision-making.

High to low pneumococcal vaccine coverage	Robustness of Policies & Decision-Making										R A N K	SCORE
	Early or Late Adopter	Manufacturer requirements	Surveillance	Health Security driven	C-E driven	NITAG- working groups	PCV policy	HZV policy	Nat'l Aging Strategy	Nat'l Immunization Strategy		
UK	2	1	2	1	2	2	1	2	1.5	2	2	16.5
US	2	2	2	1	1	2	2	2	1	2	1	17
Mexico	2	2	1	2	1	0	0	0	2	2	9	12
Korea	2	2	2	0	1	1	0	2	1	0	12	11
Colombia	0	2	1	1	1	1	1	0	1	2	15	10
Australia	1	2	2	2	1	2	1.5	2	1	2	2	16.5
Spain	2	2	1	1	1	0	1	0	1	0	17	9
Canada	1	2	1	1	1	2	2	2	1	2	5	15
Ireland	1	2	1	0	1	0	2	0	1	0	19	8
Germany	2	1	2	1	1	2	2	2	1	0	7	14
Belgium	2	1	1	0	1	1	2	1	2	0	12	11
Taiwan	2	2	1	2	1	0	0	0	0	0	20	8
Japan	0	1	1	2	1	0	0	1	1	0	23	7
Norway	1	2	1	0	1	0	0	2	1	0	20	8
UAE	1	0	1	1	0	0	1	2	0	2	20	8
Argentina	1	1	1	2	0	2	2	0	2	0	12	11
Saudi Arabia	1	0	1	2	0	0	0	0	0	0	29	4
Italy	2	2	1	2	1	0	2	2	2	2	4	16
China	0	0	1	2	1	0	0	0	1	0	27	5
Turkey	1	2	1	2	1	0	0	0	1	1	17	9
Brazil	0	0	1	1	1	1	2	0	2	2	15	10
Denmark	1	2	1	0	0	0	0	0	0	0	29	4
France	1	2	1	1	1	2	2	2	1	0	8	13
Greece	2	2	1	2	0	0	0	0	0	0	23	7
Hong Kong	1	0	1	2	1	0	2	0	0	0	23	7
India	0	1	1	1	0	0	0	0	1	0	14	4
Malaysia	0	2	1	1	1	0.5	2	0	1	0	19	8.5
New Zealand	1	2	2	2	0	0	1	1	1	2	9	12
Peru	0	2	1	0	0	0	0	0	1	0	29	4
Philippines	0	1	1	1	0	0	0	0	1	0	29	4
Russia	0	1	1	1	1	0	0	0	1	0	27	5
Sweden	2	2	1	1	2	0	2	2	0	0	9	12
Switzerland	0	2	1	1	0	0	0	0	0	0	29	4
Netherlands	2	1	2	0	1.5	2	1.5	1.5	1	2	6	14.5

scoring:  2  1.5  1  0.5  0

Source: Privor- Dumm et al. 2020. [2]

**Table 2:** Country scores on program implementation.

High to low pneumococcal vaccine coverage	Promotion of Implementation & Uptake														Rank	Score
	Public Financing for Vaccines			Vaccine Registry		Availability of Coverage Data			Advocacy	Influence of champions	Access	Equity focus	Degree of Centralization			
	Influenza	Pneumococcal	Herpes Zoster	Adult	Pediatric	Influenza	Pneumococcal	Herpes Zoster					Adult Vaccine Delivery	Health System Delivery		
UK	2	2	2	2	2	2	2	2	1	0	2	0	2	2	1	23
US	1.5	1.5	1.5	1	1	2	2	2	2	1	2	1	1	1	4	20.5
Mexico	2	2	0	1	1	1	1	0	1	1	1	1	1	1	10	14
Korea	2	0	0	2	2	2	2	2	2	1	2	0	1	1	5	19
Colombia	2	1	0	2	2	1	1	0	1	1	1	0	2	0	10	14
Australia	2	1	2	2	2	1	1	1	2	1	2	2	1	1	3	21
Spain	2	1	1	0	2	1	1	0	1	1	0	0	1	2	14	13
Canada	2	2	1	1	1	2	2	1	2	2	1	1	1	0	5	19
Ireland	2	0	0	1	1	2	2	0	1	1	2	0	0	2	10	14
Germany	2	2	0	1	2	2	1	0	0	1	0	0	1	0	17	12
Belgium	1	1	0	1	1	1	1	0	1	1	1	0	2	1	17	12
Taiwan	2	0	0	0	1	1	1	0	1	1	0	0	1	1	23	9
Japan	2	1	0	0	2	0	1	0	1	1	1	0	0	0	23	9
Norway	2	1	0	2	2	1	1	0	1	1	0	1	2	2	8	16
UAE	2	2	2	2	2	0	1	0	0	1	1	0	2	0	9	15
Argentina	2	0	0	0	1	1	1	0	1	2	1	1	2	0	17	12
Saudi Arabia	2	0	0	0	2	0	0	0	0	0	1	0	0	2	28	7
Italy	2	2	2	1	1	2	1	1	1	1	0	2	1	1	7	18
China	1	1	0	0	1	1	1	0	1	1	1	0	1	2	20	11
Turkey	2	2	0	0	0	1	1	0	1	1	1	0	0	0	23	9
Brazil	2	1	0	1	2	2	0	0	1	2	1	1	1	0	10	14
Denmark	2	0	0	2	2	1	0	0	1	1	0	0	2	2	14	13
France	2	1	0	0	0	1	0	0	1	1	1	0	0	0	28	7
Greece	2	2	0	0	0	0	0	0	1	1	0	1	0	0	28	7
Hong Kong	2	2	0	0	1	1	0	0	1	1	2	0	0	0	21	10
India	0	0	0	0	0	1	0	0	1	1	1	0	1	0	32	5
Malaysia	0	0	0	0	1	1	0	0	1	1	0	0	2	2	27	8
New Zealand	2	2	2	2	2	2	0	0	2	1	2	2	1	2	2	22
Peru	0	0	0	0	1	0	0	0	1	1	1	0	0	0	33	4
Philippines	2	2	0	0	2	1	0	0	1	1	1	0	0	0	21	10
Russia	0	0	0	0	0	1	0	0	0	0	1	0	1	1	33	4
Sweden	1	1	0	0	2	1	0	0	1	1	2	0	0	0	23	9
Switzerland	1	0	0	0	2	1	0	0	1	1	1	0	0	0	28	7
Netherlands	2	0	0	1	2	1	0	0	1	1	2	0	2	1	14	13
scoring: <div><div></div>2</div> <div><div></div>1.5</div> <div><div></div>1</div> <div><div></div>0.5</div> <div><div></div>0</div>																


Source: Privor-Dumm et al. 2020 [2]

**Table 3:** Link between funding and influenza vaccination coverage in 30 EU/EEA countries.

Country	Coverage rate in funded countries (N=24)	Average coverage rate in non-funded countries (N=4)
<b>Average</b>	<b>44%</b>	<b>12%</b>
Austria		18%
Belgium	59%	
Bulgaria		4%
Croatia	29%	
Cyprus	26%	
Czech	23%	
Denmark	52%	
Estonia		15%
Finland	47%	
France	52%	
Germany	39%	
Greece	74%	
Hungary	24%	
Iceland	55%	
Ireland	71%	
Italy	55%	
Latvia	12%	
Lichtenstein	20%	
Luxembourg	40%	
Malta	53%	
Netherlands	61%	
Norway	57%	
Poland		10%
Portugal	61%	
Slovakia	12%	
Slovenia	19%	
Spain	66%	
Sweden	53%	

Sources: Eurostat [3] & OECD [4]


Figure 2: Total government expenditure on health as a percentage of GDP, EU/EA, 2019.



\* provisional  
\*\* estimated


Sources: Eurostat. 2021. [5]

**Figure 3: Maximal vaccination cost throughout life in Germany.**




Source: Ethgen et al. 2016. [6]

**Figure 5: Maximal vaccination cost throughout life in France.**




Source: Ethgen et al. 2016. [6]

**Figure 4: Maximal vaccination cost throughout life in England.**



Source: Ethgen et al. 2016. [6]


**Figure 6: Maximal vaccination cost throughout life in Italy.**



Source: Ethgen et al. 2016. [6]




**Figure 7: Maximal vaccination cost throughout life in Spain.**




Source: Ethgen et al. 2016. [6]

**Figure 9: Maximal vaccination cost throughout life in Portugal.**



Source: Ethgen et al. 2016. [6]

**Figure 8: Maximal vaccination cost throughout life in Sweden.**



Source: Ethgen et al. 2016. [6]

## References

- Schneider, Anne Larason and Helen Ingram. 1997. Policy Design for Democracy. Lawrence, Kansas: University Press of Kansas, page 74. <https://catalogue.nla.gov.au/Record/1623565>
- Privor-Dumm, Lois A., Gregory A. Poland, Jane Barratt, David N. Durrheim, Maria Deloria Knoll, Prarthana Vasudevan, Mark Jit, Pablo E. Bonvehí, Paolo Bonanni, and International Council on Adult Immunization. "A Global Agenda for Older Adult Immunization in the COVID-19 Era: A Roadmap for Action." Vaccine 39, no. 37 (August 31, 2021): 5240–50. <https://doi.org/10.1016/j.vaccine.2020.06.082>
- Statistics | Eurostat." Accessed January 7, 2022. [https://ec.europa.eu/eurostat/databrowser/view/hlth\\_ps\\_immu/default/table?lang=en](https://ec.europa.eu/eurostat/databrowser/view/hlth_ps_immu/default/table?lang=en)
- The OECD. "Health Care Use - Influenza Vaccination Rates - OECD Data." Accessed January 7, 2022. <http://data.oecd.org/healthcare/influenza-vaccination-rates.htm>
- Eurostat. Total general government expenditure on health, 2019 (% of GDP) [https://ec.europa.eu/eurostat/statistics-explained/index.php?title=File:Total\\_general\\_government\\_expenditure\\_on\\_health\\_2019\\_\(%25\\_of\\_GDP\).png](https://ec.europa.eu/eurostat/statistics-explained/index.php?title=File:Total_general_government_expenditure_on_health_2019_(%25_of_GDP).png)
- Ethgen, Olivier, Murielle Cornier, Emilie Chriv, and Florence Baron-Papillon. 2016. "The Cost of Vaccination throughout Life: A Western European Overview." Human Vaccines and Immunotherapeutics 12 (8): 2029–37. <https://doi.org/10.1080/21645515.2016.1154649>

